发明名称 FORMULATIONS OF AZAINDOLE COMPOUNDS
摘要 A pharmaceutical composition comprises: a) 5 wt % to 95 wt % of a HCl salt of Compound (1).xH2O by the weight of the pharmaceutical composition, wherein x is from 0 to 3; and b) 5 wt % to 95 wt % of a filler by the weight of the pharmaceutical composition. Another pharmaceutical composition comprises: a) 1 mg/mL to 20 mg/mL of Compound (1) in water; and b) 0.01 M to 0.1 M of a pharmaceutically acceptable pH modifier. A method of preparing a pharmaceutical composition, comprising providing a mixture of Compound (1) that includes the HCl salt of Compound (1).xH2O and the filler. Another method of preparing a pharmaceutical composition comprises mixing the HCl salt of Compound (1).xH2O and the pH modifier to form 1 mg/mL to 20 mg/mL of Compound (1) in water. Methods of reducing the amount of influenza viruses, inhibiting the replication of influenza viruses, and treating influenza each independently employ such pharmaceutical compositions.
申请公布号 US2016250213(A1) 申请公布日期 2016.09.01
申请号 US201615150497 申请日期 2016.05.10
申请人 Vertex Pharmaceuticals Incorporated 发明人 Simone Eric Arthur;Sanghvi Tapan;Banda Alamelu;Stavropoulos Katherine
分类号 A61K31/506;A61K31/4965;A61K31/16;A61K31/351;A61K9/20;A61K45/06 主分类号 A61K31/506
代理机构 代理人
主权项 1. A pharmaceutical composition comprising: a) a HCl salt of Compound (1).xH2O wherein Compound (1) is represented by the following structural formula:wherein x is from 0 to 3; and b) one or more excipients comprising a filler, a disintegrant agent, a wetting agent, a binder, a glidant, a lubricant, or any combination thereof, wherein the HCl salt of Compound (1).xH2O has a concentration of 5 wt % to 95 wt % by weight of the composition, and the one or more excipients has a concentration of 5 wt % to 95 wt % by weight of the composition.
地址 Boston MA US